Quick Facts

• Utilized for the care of nasal symptoms associated with seasonal allergic rhinitis (hay fever).
• Appropriate for managing perennial allergic rhinitis symptoms.
• Contributes to the treatment of nasal polyps in adult patients.

Mometix-AQ is an agent approved for intranasal use to assist in the management of certain conditions affecting the nasal passages.

Its primary use is for the care of nasal symptoms related to allergic rhinitis. This includes addressing the manifestations of both seasonal allergic rhinitis, commonly known as hay fever, and perennial allergic rhinitis, which occurs year-round. It may help alleviate symptoms such as sneezing, nasal stuffiness, an increase in clear nasal fluid, and nasal itchiness.

Furthermore, Mometix-AQ is indicated for use in adult patients (18 years of age and older) to contribute to the treatment of nasal polyps. Nasal polyps are benign growths on the lining of the nose or sinuses that can cause obstruction and congestion.

In some contexts, the medication is also appropriate for the prevention of nasal symptoms associated with seasonal allergic rhinitis in patients aged 12 years and older, when initiated in advance of the known allergen exposure.

Official Eligibility and Contraindications

Mometasone Furoate Nasal Spray, containing the corticosteroid Mometasone Furoate, is subject to specific regulatory rules defining who is eligible to use the medicine.

Absolute Contraindications (Prohibited Use)

Use of this medicine is contraindicated and strictly prohibited for individuals who have a known hypersensitivity or allergy to mometasone furoate or any of the formulation's ingredients.

Furthermore, use is prohibited for patients with an untreated localized infection involving the nasal lining (e.g., Herpes simplex), and following recent nasal surgery or trauma until the healing process is fully complete.

Age-Related Eligibility

Condition	Minimum Age for Approved Use
Allergic Rhinitis Treatment	3 years of age and older
Nasal Polyps Treatment	18 years of age and older (Adults only)

The medicine's safety and efficacy for allergic rhinitis have not been established in children under 3 years of age. Treatment for nasal polyps is limited exclusively to the adult population.

Conditional Use and Restrictions

Use requires caution in patients with active or quiescent tuberculous infections of the respiratory tract or untreated systemic infections (fungal, bacterial, or viral). Patients being transferred from long-term systemic corticosteroids require careful attention due to the potential for adrenal insufficiency.

During pregnancy and lactation, use is not recommended unless the potential benefit to the mother justifies any potential risk. Infants born to mothers who used corticosteroids during pregnancy must be carefully observed for signs of hypoadrenalism.

Interactions with other medicines and products

Potential Drug-Drug Interactions

Mometix-AQ (mometasone furoate) nasal spray has a low systemic bioavailability, minimizing the potential for drug interactions. However, interactions with certain classes of medicines are documented due to the way the active ingredient is metabolized in the body. Mometasone furoate is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system.

Product Category
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Cobicistat, Ritonavir)

Concomitant use with strong CYP3A4 inhibitors is expected to increase the plasma concentrations of mometasone furoate, raising the risk of systemic corticosteroid side effects, including adrenal suppression. This combination is generally not recommended unless the potential benefit justifies the increased risk. If co-administration is unavoidable, patients should be closely monitored for signs of systemic corticosteroid effects.

Other Interacting Substances

In a clinical study, co-administration of mometasone furoate nasal spray with the antihistamine loratadine showed no evidence of drug interaction.

Mometix-AQ, containing mometasone furoate, functions as an inhibitor of inflammatory mediator synthesis and release. This action is initiated by the binding of the compound to intracellular glucocorticoid receptors. This binding event results in the translocation of the receptor-ligand complex to the nucleus, where it modulates gene transcription.

The complex increases the transcription of anti-inflammatory proteins, such as lipocortin-1, and simultaneously decreases the transcription of pro-inflammatory genes, including those encoding cytokines (e.g., IL-1, IL-6), chemokines, and cyclooxygenase-2 (COX-2).

At a cellular level, Mometix-AQ modulates mast cell activity and inhibits the migration and activation of inflammatory cells (e.g., eosinophils and neutrophils) into target tissues. This cascade of events leads to a reduction in local tissue edema and vascular permeability and decreases cellular infiltration, representing a system-level physiological modulation.

Mometix-AQ is an aqueous suspension nasal spray designated for intranasal use only. The proper use protocol mandates that the device must be shaken well before each dose and requires priming (usually 10 actuations) before initial use or after a specified period of non-use to ensure a consistently accurate metered dose is delivered. The prescribed frequency for most conditions is once daily.

For adults and adolescents 12 years and older, the usual regimen is two sprays (100 mu g) in each nostril once daily, for a total daily dose of 200 mu g. For the management of nasal polyps, the regimen is two sprays per nostril twice daily, resulting in a maximum daily dose of 400 mu g. For children aged 2 to 11 years, the approved regimen is one spray (50 mu g) in each nostril once daily, resulting in a total daily dose of 100 mu g.

When administering the spray, the nozzle should be aimed slightly away from the nasal septum. The medication is typically used as a regular, long-term maintenance treatment. For seasonal allergies, it may be initiated 2 to 4 weeks prior to anticipated allergen exposure. If a dose is missed, the missed dose should be skipped if it is near the time of the next scheduled dose, followed by a return to the regular regimen. The device must be discarded after the labeled number of sprays has been completed.

Mometix-AQ: Recent Clinical Evidence

Overview of Key Findings

Clinical research investigated the drug's properties and how they might affect inflammation associated with conditions like allergic rhinitis. Research reported findings that included lower symptom severity and duration scores in some participants during the course of the studies. These findings were primarily drawn from Phase 3 Randomised Controlled Trials (RCTs) that were conducted.

Research evaluated the relationship between the drug’s use and measures of disease activity, including flare-up frequency. One key study documented changes in patient quality of life measures during the observation period.

---

Specific Study Details

Duration and Comparisons

Studies often evaluated treatment courses lasting at least six months. The research has explored how the measurements taken for this drug differed from those taken for older treatments in studies measuring the frequency of hospitalizations.

Study Population and Measured Outcomes

The majority of research to date has focused on adults aged 18 to 65 with a confirmed diagnosis of the condition. In some studies, participants with pre-existing heart conditions were excluded from participation.

Primary outcomes measured in the largest studies commonly included:

• Changes in validated symptom severity scores (e.g., DAS28, HAQ).
• The reported frequency of disease flare-ups.
• The documentation of adverse events and reasons for withdrawal from the study.

The final results described the study outcomes, including measures of effect and adverse events.

Key Studies & References Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision (Clinical Guidelines)

Common questions about Mometix-AQ (FAQ)

---

Q: Why is it so important to prime the device?

A: Official product instructions state that priming the nasal spray device is required before the first use or after a specified period of non-use. This step is necessary to help ensure the device delivers a consistent, accurate metered dose of the medicine.

Q: What happens if I miss a dose?

A: Official patient information states that if a dose is missed, it can be used as soon as it is remembered. However, if it is already near the time for your next scheduled dose, the label specifies to skip the missed dose and continue with the regular schedule. The labeling specifies not to use two doses simultaneously to catch up.

Q: What is the dosage for children 6 years old?

A: According to the official product label, the approved regimen is specified for the broad age category of children aged 2 to 11 years. The full dosage regimen, including the exact number of sprays for the child's age group, is determined and prescribed by a healthcare provider.

Q: How does this medication work to stop inflammation in the nose?

A: Mometix-AQ is classified as a glucocorticoid and acts as a powerful anti-inflammatory agent. Regulatory documents explain that it works by binding to intracellular receptors, which contributes to inhibiting the release of inflammatory chemicals (like cytokines) and lessening swelling in the nasal lining.

Q: Which other medicines interact with this spray?

A: While the medicine has a low risk of systemic drug interactions, official information warns about combining it with strong inhibitors of the CYP3A4 enzyme system (a specific liver enzyme). This combination can increase the concentration of the drug systemically, which carries a potential risk of systemic corticosteroid side effects.

Q: What are the most serious side effects I should look out for?

A: Serious adverse reactions that have been documented include the potential for nasal septal perforation (a hole in the nasal cartilage) and severe hypersensitivity reactions (like anaphylaxis). Additionally, Glaucoma or Cataracts are specific ocular effects that are explicitly associated with very long-term use, according to regulatory documents.

Q: Is there a specific way to clean the nozzle or device?

A: Yes, the official directions for use include specific instructions for cleaning the plastic applicator or nozzle. Following these cleaning directions helps prevent the device from blocking up and is essential to maintaining consistent and accurate dosing.

Q: How long will it take for the spray to start working?

A: Studies and official information indicate that the anti-inflammatory effects of the medicine begin relatively quickly. However, the maximum clinical benefit for symptom relief may take up to one to two weeks of regular use to become noticeable.

Q: How do I know the device is empty and I need a new one?

A: The drug is supplied in a bottle designed to deliver a specific, pre-determined number of metered sprays (e.g., 120). Official guidance requires that the device be discarded after that labeled number of sprays has been used, or after a specific number of days following its first use, whichever comes first.

Q: What should I do if the spray accidentally goes into my eyes?

A: The medicine is strictly intended for intranasal use only. The official label warns about the potential for ocular side effects, indicating that contact with the eyes should be avoided, as the medicine is intended only for intranasal administration.

Q: Can I use this spray if I am pregnant?

A: Official regulatory documents indicate that use during pregnancy and lactation is generally not recommended. It may only be considered if a healthcare provider determines the potential benefit to the mother justifies any potential risk. Infants of mothers who used corticosteroids during pregnancy must be monitored.

How to Store and Dispose of Mometix-AQ?

Storage of Mometix-AQ (mometasone furoate) Nasal Spray must adhere to specific regulatory conditions to maintain product stability and safety.

---

Required Storage and Protection

The medicine must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be kept from freezing and stored away from heat, moisture, and direct light. The medicine must be kept in its original container, tightly closed, and out of the reach and sight of children.

---

Shelf-Life and Disposal

Regulatory labeling requires that the bottle be discarded after 120 sprays have been used or 75 days after the first use, whichever comes first. Unused or expired product should not be kept. Users must consult a healthcare professional or pharmacist for specific instructions on how to properly dispose of the medicine and should not flush it down a toilet or pour it into a drain.